Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Q32 Bio (Nasdaq: QTTB) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The clinical stage biotechnology company, which specializes in developing biologic therapeutics for immune homeostasis restoration, will deliver a virtual company presentation on Tuesday, February 11, 2025, at 4:00 p.m. E.T.
Interested parties can access the presentation webcast through Q32 Bio's website at www.q32bio.com on the Events and Presentations page. The presentation recording will remain available for 90 days after the event.
Q32 Bio (Nasdaq: QTTB) ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sui Life Sciences di Oppenheimer. L'azienda biotecnologica in fase clinica, specializzata nello sviluppo di terapie biologiche per il ripristino dell'omeostasi immunitaria, presenterà un intervento aziendale virtuale il martedì 11 febbraio 2025, alle 16:00 E.T.
Le parti interessate possono accedere al webcast della presentazione attraverso il sito web di Q32 Bio su www.q32bio.com nella pagina Eventi e Presentazioni. La registrazione della presentazione sarà disponibile per 90 giorni dopo l'evento.
Q32 Bio (Nasdaq: QTTB) ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. La empresa de biotecnología en etapa clínica, que se especializa en el desarrollo de terapias biológicas para la restauración de la homeostasis inmunitaria, realizará una presentación virtual de la empresa el martes 11 de febrero de 2025, a las 4:00 p.m. E.T.
Las partes interesadas pueden acceder al webcast de la presentación a través del sitio web de Q32 Bio en www.q32bio.com en la página de Eventos y Presentaciones. La grabación de la presentación estará disponible por 90 días después del evento.
Q32 Bio (Nasdaq: QTTB)는 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다. 면역 항상성 회복을 위한 생물학적 치료법 개발을 전문으로 하는 임상 단계의 생명공학 회사는 2025년 2월 11일 화요일, 오후 4시 E.T.에 가상 회사 발표를 진행할 예정입니다.
관심 있는 분들은 Q32 Bio의 웹사이트 www.q32bio.com의 이벤트 및 발표 페이지를 통해 발표 웹캐스트에 접근할 수 있습니다. 발표 녹화는 행사 후 90일간 이용 가능합니다.
Q32 Bio (Nasdaq: QTTB) a annoncé sa participation à la 35e Conférence Annuelle sur la Santé et les Sciences de la Vie d'Oppenheimer. La société de biotechnologie en phase clinique, qui se spécialise dans le développement de thérapies biologiques pour la restauration de l'homéostasie immunitaire, effectuera une présentation virtuelle de l'entreprise le mardi 11 février 2025, à 16h00 E.T.
Les parties intéressées peuvent accéder au webinaire de présentation via le site web de Q32 Bio à www.q32bio.com sur la page Événements et Présentations. L'enregistrement de la présentation restera disponible pendant 90 jours après l'événement.
Q32 Bio (Nasdaq: QTTB) hat seine Teilnahme an der 35. Jährlichen Gesundheits- und Lebenswissenschaften-Konferenz von Oppenheimer angekündigt. Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf die Entwicklung biologischer Therapeutika zur Wiederherstellung der Immunhomäostase spezialisiert hat, wird am Dienstag, den 11. Februar 2025, um 16:00 Uhr E.T. eine virtuelle Unternehmenspräsentation halten.
Interessierte können auf den Präsentations-Webcast über die Webseite von Q32 Bio unter www.q32bio.com auf der Seite Veranstaltungen und Präsentationen zugreifen. Die Aufzeichnung der Präsentation bleibt für 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.
Q32 Bio's program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases being evaluated in a Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Q32 Bio's program for innate immunity, ADX-097, being evaluated in a Phase 2 program, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Contacts:
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-oppenheimers-35th-annual-healthcare-life-sciences-conference-302367870.html
SOURCE Q32 Bio
FAQ
When is Q32 Bio (QTTB) presenting at the Oppenheimer Healthcare Conference 2025?
How long will Q32 Bio's (QTTB) Oppenheimer Conference presentation be available for replay?
Where can investors watch Q32 Bio's (QTTB) Oppenheimer Conference presentation?
Is Q32 Bio's (QTTB) presentation at the Oppenheimer Conference virtual or in-person?
